ISH-IF showed co-localization of CB2 mRNA in around 20-40% of immune cells, and 25% in KP tumor cells, suggesting TME cell-mediated and/or possible direct effects on tumor cells by CB2. This evidence concerns the gene CNR2 and neoplasm.